Intranasal (Optinose Bidirectional Nose-to-brain Device) Versus Intravenous Slow Infusion of Oxytocin - a Randomized, Placebo- Controlled Double-blind, Double-dummy 4-period Cross-over Study in Healthy Adult Volunteers Evaluating Brain Functional Magnetic Resonance Imaging Changes, Cognitive Response, Heart Rate Variability, Plasma Pharmacokinetics and Saliva Concentration After Single-dose Oxytocin 8 or 24 International Units (IU) Intranasally or 1 IU as Slow Intravenous Infusion
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2015
At a glance
- Drugs Oxytocin (Primary) ; Oxytocin (Primary)
- Indications Autistic disorder
- Focus Pharmacodynamics
- Sponsors OptiNose
- 06 Oct 2015 Initial results published in the peer-reviewed journal Translational Psychiatry, as per Optinose media release.
- 15 Jul 2015 Results published in an OptiNose media release.
- 22 Nov 2013 New trial record